B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-phase study tests a new tablet, FXS0683, in about 228 adults with certain blood cancers (like lymphoma, leukemia, or myelodysplastic syndromes) that have returned or not improved after standard treatments. The main goals are to find a safe dose and see if the drug can …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 16, 2026 23:07 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Not yet recruitingThis study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to attack cancer cells with two targets (CD19 and CD22). It is for adults with leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to check safety and how well t…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in adults with B-cell cancers (like certain lymphomas) that have come back or not responded to prior treatments. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safes…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Double-Pronged CAR t cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check the safety …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New study aims to make CAR-T therapy safer for lymphoma patients
Disease control Not yet recruitingThis study compares two chemotherapy regimens (bendamustine vs. fludarabine/cyclophosphamide) given before CAR-T cell therapy in 92 adults with B-cell lymphoma. The goal is to see which regimen causes fewer severe side effects like cytokine release syndrome, febrile neutropenia, …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New combo therapy targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study tests a new drug, NX-5948, combined with other medicines in adults with B-cell blood cancers like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The goal is to see if the combination is safe and helps control the cancer. About 150 people will …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New combo aims to keep lymphoma in check after CAR-T
Disease control Not yet recruitingThis study tests whether taking zanubrutinib (a targeted pill) after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults who have already had or are about to have CAR-T therapy will take zanubrutinib as a maintenance treatment. The main …
Matched conditions: B-CELL LYMPHOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 01, 2026 17:56 UTC